, thereby increasing the flux of H 2 O 2 , resulting in increased cytotoxicity. We hypothesized that a multimodal treatment approach, utilizing a combination of P-AscH -, ionizing radiation and MnT4MPyP, would result in significant flux of H 2 O 2 and pancreatic cancer cytotoxicity. P-AscH -with MnT4MPyP increased the rate of oxidation of P-AscH -and produced radiosensitization in all pancreatic cancer cell lines tested. Three-dimensional (3D) cell cultures demonstrated resistance to P-AscH -, radiation or MnT4MPyP treatments alone; however, combined treatment with P-AscH -and MnT4MPyP resulted in the inhibition of tumor growth, particularly when also combined with radiation. In vivo experiments using a murine model demonstrated an increased rate of ascorbate oxidation when combinations of P-AscH -with MnT4MPyP were given, thus acting as a radiosensitizer. The translational potential was demonstrated by measuring increased ascorbate oxidation ex vivo, whereby MnT4MPyP was added exogenously to plasma samples from patients treated with P-AscH -and radiation. Combination treatment utilizing P-AscH -, manganoporphyrin and radiation results in significant cytotoxicity secondary to enhanced ascorbate oxidation and an increased flux of H 2 O 2 . This multimodal approach has the potential to be an effective treatment for pancreatic ductal adenocarcinoma. Ó 2019 by Radiation Research Society
INTRODUCTION
Ductal adenocarcinoma of the exocrine pancreas (PDAC) represents 85% of all pancreatic neoplasms and is the fourth overall leading cause of cancer-related deaths in the U.S. (1) . The National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) data gave estimates of 53,070 new pancreatic cancers and 43,090 deaths for 2017 (2) . Unfortunately, the prognosis for PDAC has failed to show major improvement, with current five-year survival rates at merely 7.7% (2) . PDAC remains a highly deadly disease with a notable lack of treatment progress. For the majority of patients with locally advanced or distant disease, chemotherapy (either single or multidrug), radiation therapy and in some instances, a combination chemoradiation therapy, remain options for palliation and improving quality of life (3) . However, the side effect profile is significant, highlighting a need for sensitizing agents capable of selectively increasing tumor toxicity without detrimental consequences to normal tissue. Pharmacological ascorbate (intravenous high-dose vitamin C, P-AscH -) has demonstrated potential as one such agent with significant PDAC cytotoxicity in vitro and in vivo (4) (5) (6) . Phase 1 clinical trials using P-AscH -have shown promise in both PDAC and other aggressive cancers, with very few side effects and suggestion of survival benefit when used for patients with advanced disease (7) (8) (9) .
Ascorbate functions as an antioxidant for cells and organ systems at physiologic concentrations and pH by readily donating an electron to potentially harmful free radical species (10) . However, at high doses, achievable only by intravenous administration, P-AscH -becomes a prodrug for delivery of H 2 O 2 to tissue (6, 10, 11) . Normal cells with a full complement of antioxidant enzymes are capable of managing this oxidative flux while cancer cells become overwhelmed (12) (13) (14) . The fundamental difference between the oncologic drug, P-AscH -, and oral vitamin C is the resulting bioavailability (15) . Millimolar plasma concentrations are required to generate the extracellular oxidative flux necessary for chemotherapeutic effect, a level only achievable via parenteral administration (16) .
The oxidative consequences initiated by P-AscH -have been extensively investigated by our laboratory and others. The dominant form of P-AscH -in physiological settings is the ascorbate monoanion (AscH -); it can donate two electrons to O 2 , forming H 2 O 2 , which leads to cancer cell toxicity (6) . In the presence of redox active catalytic metal ions (i.e., iron, copper and manganese), this reaction can be significantly accelerated (17, 18) .
Manganoporphyrins (19, 20) . Of the variety of MnPs previously tested, MnT4MPyP demonstrated the greatest effect on ascorbateinduced cytotoxicity in PDAC, consistent with its favorable reduction potential (21) . Indeed, MnPs combined with P-AscH -have demonstrated enhanced cytotoxicity to pancreatic cancer cells in vitro and in vivo by increasing the flux of H 2 O 2 generated by P-AscH - (21, 22) . Perhaps equally important, MnPs have already been tested in vivo and have shown minimal systemic toxicity (19) . Furthermore, they have been shown to have radioprotective properties in normal tissue (23) . Combined with PAscH -, MnPs synergistically enhance cytotoxicity and may be a promising adjuvant to P-AscH -for the treatment of PDAC.
Ionizing radiation is a standard-of-care treatment for PDAC in many clinical situations, including locally advanced disease, node-positive disease, positive tumor margins and large obstructing tumors. In addition to direct damage, radiation also induces DNA damage in a similar fashion to P-AscH -, by generating ROS that inflict oxidative damage to proteins, lipids and DNA (24) . Previously published work has indicated a synergistic effect between radiation and P-AscH -resulting in enhanced tumor toxicity and protection of normal cells (4, (25) (26) (27) (28) . The selective cytotoxicity in malignant cells compared to normal cells is thought to be due to several different factors, including low levels of antioxidant enzymes, high endogenous levels of ROS and inefficient DNA repair mechanisms (6, (25) (26) (27) (28) (29) . We hypothesized that MnT4MPyP would enhance the radiation-induced cytotoxicity of PDAC by increasing the rate of oxidation of PAscH -. Our study demonstrates that combination treatment with MnT4MPyP and P-AscH -radiosensitizes PDAC cells but not normal cells, and generates higher rates of ascorbate oxidation (i.e., higher fluxes of H 2 O 2 ), which increases cancer cell toxicity in cell culture and simulated tissue microenvironments. Furthermore, in tumor xenografts there were increased levels of Asc -in blood and decreased tumor volumes with combined P-AscH -, MnT4MPyP and radiation treatment. Finally, the addition of MnT4MPyP to human plasma samples, collected from clinical trial participants receiving P-AscH -as part of their PDAC treatment, resulted in increases in the rate of ascorbate oxidation, as indicated by the high levels of Asc -, suggesting translational potential.
MATERIALS AND METHODS

Cell Culture and Reagents
The human pancreatic cancer cell lines MIA PaCa-2 and PANC-1 were purchased from ATCCt (Gaithersburg, MD) and passaged fewer than 20 times in DMEM with 10% fetal bovine serum (FBS) and 1% penicillin streptomycin (pen-strep). AsPC-1 cells were also obtained from ATCC and passaged in RPMI with 10% FBS and 1% pen-strep. The non-tumorigenic HPV16-E6E7 immortalized normal pancreatic ductal epithelial cell line H6c7 was purchased from Kerafastt, Inc. (Boston, MA) and were maintained in keratinocyte serum-free media supplemented with epidermal growth factor (5 ng/ml) and bovine pituitary extract (50 lg/ml). Immortalized tumor-associated pancreatic stellate cells (HPSCs) were obtained from Hwang et al. (30) and maintained in DMEM with 10% FBS and 1% pen-strep. Mn(III) tetrakis(N-methylpyridinium-4-yl) porphyrin pentachloride (MnT4MPyP) was purchased from Axxora Platform (San Diego, CA) and stored in colored vials at À208C or dissolved in nanopure water and stored at 48C.
Clonogenic Survival Assay
Stock solutions of ascorbate (1.0 M, pH 7.0) were prepared, as described elsewhere (6) . Cell culture treatments were performed by adding MnT4MPyP (1.0 lM) and a nutritional dose of P-AscH -(0.2 mM) to fresh media for 1 h at 378C. At the end of 1 h, cells were irradiated to complete the treatment. Clonogenic cell survival was determined in a similar manner to previously published works (6) . After 10-14 days, surviving colonies were fixed with 70% ethanol and stained with Coomassie blue; colonies greater than 50 cells were counted under inverted light microscope. (31, 32) . The MIA PaCa-2-Luc 3D cell cultures were kept in DMEM 10% FBS and 1% pen-strep. At 24 h after creation, MIA PaCa-2-Luc cells embedded in the 3D cell cultures were imaged and quantified for baseline bioluminescent signal strength with the AMI-1000 (Spectral Instruments Imaging, Tucson, AZ) and AMIView software. Media was replaced and 3D cell cultures were subsequently treated with MnT4MPyP (2.0 lM) and/or P-AscH -(7.0 mM) for 1 h. Irradiations, 1-2 Gy, were performed at the end of 1 h and the media was replaced and cultures returned to the incubator. After 24 h, cells were reimaged for bioluminescent signal strength. PANC-1-Luc 3D cultures mixed with human pancreatic stellate cells were treated in a similar manner but for three consecutive treatments, each 48 h apart. Repeated treatments were performed on the PANC-1 cell line to account for higher ascorbate resistance in the PANC-1 cell line conferred by a greater capacity to remove H 2 O 2 compared to the MIA PaCa-2 cell line (14) .
Electronic Paramagnetic Resonance
Estimates of the steady-state concentration of ascorbate radical, [Asc - ] ss , in body fluids or media were determined as previously described elsewhere (7, 21, 22, 33) . In brief, media samples, mouse whole blood or human plasma were placed into capillary tubes and then placed into a quartz 250 3 3 mm inner diameter EPR tube (Wilmad-LabGlass, Vineland, NJ) and centered in an ER 4119HS resonator of a Bruker EMX EPR spectrometer (Bruker BioSpin; Billerica, MA). Spectra were acquired as five signal-averaged scans at room temperature using EPR standard instrument settings. 3-Carboxy-PROXYL (3-CxP CAS no. 2154-68-9, Millipore Sigma, St. Louis, MO), was used as a standard to estimate [Asc - ] ss , while considering potential saturation effects (34) .
In Vivo Studies
Thirty-day-old athymic nude mice were obtained from Harlan Sprague-Dawley, Inc. (Indianapolis, IN). Murine protocols were reviewed and approved by the Office of The Institutional Animal Care and Use Committee (IACUC). Mice were injected subcutaneously (s.c.) with 3 3 10 6 MIA PaCa-2-Luc tumor cells. Once tumors reached 3-4 mm in diameter, mice were randomized into one of four experimental treatment groups consisting of 6 to 8 mice: saline alone; saline and irradiation; MnT4MPyP and P-AscH -; and MnT4MPyP with P-AscH -and irradiation. The first day of treatment was considered day 1 and treatments continued for 24 days. Tumor growth was determined by bioluminescence imaging microscopy (mean radiance photons/s -1 /cm 2 ). Saline was given at a dose of 1 M NaCl daily. MnT4MPyP was delivered at 1 mg/kg per day s.c. PAscH -was delivered at 4 g/kg per day intraperitoneally (i.p.). A 5 Gy dose of radiation was delivered to each flank tumor on days 4, 11 and 18 of treatment. Prior to irradiation, mice were anesthetized with 80-100 mg/kg ketamine i.p. and were shielded with lead blocks to expose only the tumor-bearing flanks. Tumor growth was monitored periodically over the course of treatment using bioluminescent imaging to determine tumor burden.
Ex Vivo Studies
In separate groups of mice, cardiac blood draws were performed and mouse whole blood was evaluated for [Asc -] ss determination by EPR, as described above. Mice were sacrificed by cervical dislocation. Flank tumors were excised for processing and 4HNE staining. For the human ex vivo experiments, the blood samples were collected during the phase I trial, which was approved by The University of Iowa Human Institutional Review Board and the Protocol Review and Monitoring Committee of the Holden Comprehensive Cancer Center at The University of Iowa Hospitals and Clinics (Iowa City, IA) on December 30, 2014. The trial was listed on www.clinicaltrials.gov under NCT01852890. Informed consent was documented by use of a written consent form approved by the Investigational Review Board and The University of Iowa. Plasma samples were collected at several key points throughout treatment: before patients received any chemoradiation or P-AscH -treatments; prior to P-AscH -infusion during the third and sixth weeks of chemoradiation; and immediately after P-AscH -infusion in the third and sixth weeks of chemoradiation.
Western Blot
Mouse tumors were excised and processed to determine 4-hydroxy-2-nonenal-(4HNE) modified proteins as described elsewhere (4, 35) . 4HNE is a marker of lipid peroxidation and is a well-established marker of tissue oxidative stress (36) . Briefly, tissues were homogenized in 1.3 mM diethylenetriaminepentaacetic acid (DETA-PAC), 10 mM butylated hydroxytoluene (BHT) and a complete miniprotease inhibitor (Roche Diagnostics, Indianapolis, IN) and assayed for protein concentration utilizing the Bradford assay. Protein (50 lg) in PBS was blotted onto PVDF membranes. Blots were incubated with the primary antibody recognizing the Michael addition product of 4HNE-modified cellular proteins diluted 1:2,000 overnight at 48C (37) . Secondary antibody incubation was performed for 1 h with an HRP-conjugated goat anti-rabbit polyclonal antibody (1:25,000). Immunoreactive protein was detected using chemiluminescence (ECL Plus Western Blotting Detection System) on X-ray film. Analysis was performed by comparing 4HNE immunoreactive protein normalized to protein loading, determined by staining with India ink. Normalized average integrated densities were determined with ImageJ software (National Institutes of Health, Bethesda, MD).
Statistical Analysis
Student's t tests were used to calculate statistical significance between two treatments, and one-way ANOVA tests were used to calculate statistical significance between more than two treatments. All experiments were performed in triplicate. Standard error of the mean (SEM) is reported by the error bars. All statistical analysis, unless otherwise specified, was performed in GraphPad Prismt (LaJolla, CA). P-AscH -toxicity curves were generated using IGOR Pro version 6.36 (WaveMetrics Inc., Lake Oswego, OR).
RESULTS
Enhanced Ascorbate Oxidation Radiosensitizes PDAC
Our previously published laboratory studies demonstrated that P-AscH -radiosensitized PDAC (4). Similarly, P-AscH -in combination with MnT4MPyP as an oxidative catalyst exhibits enhanced cytotoxic effects by augmenting H 2 O 2 generation (21). Clonogenic survival assays using a combination treatment of MnT4MPyP, P-AscH -and irradiation in three PDAC cell lines demonstrated significant radiosensitization (Fig. 1A-C) . Dose modifying factors calculated at 50% iso-survival for each cell line were as follows: MIA PaCA-2 (2.7); AsPC-1 (2.6); and PANC-1 (3.1). There was no radiosensitization in the non-tumorigenic H6c7 cell line (Fig. 1D) .
In an effort to better simulate the tumor microenvironment, a 3D cell culture was created using the commercially available Cell-Mate3D system. With this technique, cells were embedded in a tissue matrix chemically composed of hyaluronic acid and chitosan (38) . The cellular component was composed of MIA PaCa-2-Luc or PANC-1-Luc tumor cells and immortalized tumor-associated human pancreatic stellate cells (HSPCs). 3D cultures were suspended in media and treated with P-AscH -, MnT4MPyP and radiation (0-2 Gy). MIA PaCa-2-Luc cells treated with MnT4MPyP alone, P-AscH -alone, 1 Gy or 2 Gy irradiation alone experienced continued cell growth over 24 h that was similar to the growth of nontreated control cultures, as shown in Fig. 2A . However, cultures treated with combination MnT4MPyP and P-AscH -exhibited declines in bioluminescent signal strength ( Fig. 2A) . When cells received combined treatment with MnT4MPyP, P-AscH -and radiation, an even greater decrease in signal strength was noted, demonstrating the enhanced cytotoxicity produced by combining all three treatment modalities, which when used individually, were not sufficient to produce tumor cytotoxicity in this MnT4MPyP AND ASCORBATE SENSITIZES PANCREATIC CANCER simulated tumor microenvironment. Similar results were seen in the PANC-1 3D culture, with the combined treatment of MnT4MPyP, P-AscH -and radiation demonstrating the greatest decline in bioluminescent signal strength ( Figure 2B ).
MnT4MPyP Increases Asc -Formation in Radiation Treatments
To determine if the increased radiosensitivity in the presence of the MnT4MPyP combined with P-AscH -was due to enhanced P- (18, 39) . Figure 3A ] ss to 770 6 150 nM (means 6 SEM, n ¼ 3, *P , 0.05 compared to P-AscH -alone).
Enhanced Ascorbate Oxidation Radiosensitizes In Vivo
We have previously demonstrated that MnT4MPyP and P-AscH -inhibits tumor growth in vivo (4, 21, 22 ). In the current experiment, we used a combination approach, i.e., MnT4MPyP with P-AscH -and radiation, to explore the potential of this treatment in vivo. MIA PaCa-2-Luc human PDAC cells were used to facilitate tumor growth measurements via bioluminescent imaging. Tumor growth curves are shown in Fig. 4A . Saline-treated mice exhibited a rapid rate of tumor growth over the duration of the experiment with a nearly ninefold increase in tumor size. The irradiation group and the MnT4MPyP and P-AscH -combined treatment group experienced similar rates of growth (1.6-and 2.1-fold difference from baseline, respectively). How- . Clonogenic survival was determined and toxicity curves were generated. For the MIA PaCa-2, AsPC-1 and PANC-1 PDAC cells (panels A-C), the resulting dose modification factors at 50% iso-survival were 2.7, 2.6 and 3.1, respectively, all of which indicated radiosensitization (*P , 0.01 vs. radiation alone, means 6 SEM, n ¼ 3 per group). In the H6c7 cells (panel D), there was no radiosensitization (P . 0.05 vs. radiation alone, means 6 SEM, n ¼ 3).
FIG. 2.
Enhanced ascorbate oxidation radiosensitizes PDAC cells in 3D culture. Panel A: MIA PaCa-2-Luc cells were mixed with human pancreatic stellate cells at a ratio of 1:19 (5% cancer cells) and suspended in a 3D cell culture matrix to simulate the tumor microenvironment. Cultures were treated with MnT4MPyP (2 lM) and P-AscH -(7 mM) for 1 h and irradiated at 0-2 Gy. The 24-h change in BOI after treatment was measured. MnT4MPyP, P-AscH -and 1 Gy or 2 Gy radiation alone had no effect on bioluminescent expression compared to control. Combination treatment with MnT4MPyP and P-AscH -resulted in a decreased bioluminescence while the addition of radiation further reduced the bioluminescence. (*P , 0.05 compared to control, means 6 SEM, n ¼ 3). Panel B: PANC-1-Luc cells were mixed with human pancreatic stellate cells in a ratio of 3:17 (15% cancer cells) and suspended in a 3D cell culture matrix and treated with MnT4MPyP (2 lM) and P-AscH -(7 mM) for 1 h and irradiated at 0-2 Gy. Treatments were repeated every 48 h for a total of three treatments. The 144-h change in BOI after all three treatments was measured, and demonstrated decreased bioluminescence in cultures treated with combination MnT4MPyP and P-AscH -. The addition of radiation further reduced the bioluminescence. (*P , 0.05 compared to control, means 6 SEM, n ¼ 3). MnT4MPyP AND ASCORBATE SENSITIZES PANCREATIC CANCER ever, the mice that received combined treatment of MnT4MPyP, P-AscH and radiation exhibited an overall regression in tumor size from their baseline measurement (means 6 SEM, n ¼ 6-8 per group, *P , 0.05 vs. saline, # P , 0.05 vs. irradiation alone and MnT4MPyP with PAscH -).
FIG. 3. MnT4MPyP increases P-
Enhanced Ascorbate Oxidation In Vivo
The average whole blood Mice that received combined treatment of MnT4MPyP, PAscH -and radiation showed the highest levels of [Asc -] ss with a mean of 160 6 35 nM, which was significantly increased compared to the other three treatment groups (means 6 SEM, n ¼ 6-8, P , 0.001). In addition, excised tumors from mice that received combined treatment of MnT4MPyP, P-AscH -and radiation demonstrated the highest levels of protein oxidation (Fig. 4C and D) . Neither radiation alone, nor MnT4MPyP and P-AscH -increased tumor 4HNE immunoreactivity from the levels measured in saline-treated mice. Only the combination of all three treatment modalities showed increased 4HNE levels within tumors.
MnT4MPyP Increases P-AscH -Oxidation in Ex Vivo Human Plasma
We sought to investigate the translational potential for MnT4MPyP to increase ascorbate oxidation in humans receiving P-AscH -and radiation therapy for PDAC. We used plasma samples collected from our phase I clinical trial (NCT01852890) to test for changes in [Asc -] ss with the
FIG. 4.
Enhanced ascorbate oxidation radiosensitizes in vivo PDAC growth and increases tumor oxidative stress. Panel A: Mice were injected subcutaneously with 3 3 10 6 MIA PaCa-2-Luc tumor cells. Once tumors could be imaged by bioluminescence, mice were randomized into one of four experimental treatment groups: saline alone; saline and irradiation; MnT4MPyP and P-AscH -; and MnT4MPyP with P-AscH -and irradiation. The first day of treatment was considered day 1 and treatments continued for 24 days. Saline was given at a dose of 1 M NaCl daily. MnT4MPyP was delivered at 1 mg/kg per day s.c. P-AscH -was delivered at 4 g/kg per day i.p. A dose of 5 Gy radiation was delivered to each flank tumor on days 4, 11 and 18 of treatment. In animal tumors treated with radiation alone or with combination MnT4MPyP and P-AscH -, tumor growth inhibition was observed compared to saline-treated animals (*P , 0.05, means 6 SEM, n ¼ 12-14). However, mice treated with MnT4MPyP combined with P-AscH -and irradiation had the greatest inhibition of tumor growth compared to saline (*P , 0.05) and irradiation alone or MnT4MPyP combined with P-AscH -( # P , 0.05, means 6 SEM). Panel B: [Asc -] ss was determined by EPR, demonstrating significant increase in groups of mice treated with MnT4MPyP combined with PAscH -(30 nM 6 7, n ¼ 6) and MnT4MPyP combined with P-AscH -and irradiation (160 nM 6 35, n ¼ 6, *P , 0.05, means 6 SEM). Panel C: Representative protein oxidation as measured by 4HNE in tumors from each group after treatment with saline, MnT4MPyP, PAscH -and 5 Gy irradiation. Panel D: 4HNE immunoreactive protein quantified from tumor samples using ImageJ software, normalized to saline controls. Tumors of mice treated with MnT4MPyP combined with P-AscH -and irradiation experienced higher levels of protein oxidation compared to MnT4MPyP combined with P-AscH -(*P , 0.05, means 6 SEM). addition of 1.0 lM of MnT4MPyP. Plasma specimens from six patients receiving P-AscH -five days per week during their daily radiation treatments were also collected. A total of nine plasma samples were used for the control analysis, consisting of PDAC patients who received chemoradiation therapy but did not receive P-AscH -as part of their treatment. Control patient samples were collected prior to treatment, during the third and sixth weeks of the standard chemoradiation cycle. Each plasma sample was tested for [Asc -] ss . The control, pretreatment and pre-infusion levels were comparable, while the P-AscH -post-infusion plasma samples were significantly higher, as would be expected (Supplementary Fig. S1 ; http://dx.doi.org/10.1667/ RR15189.1.S1). All plasma samples were then spiked with MnT4MPyP (1.0 lM) and the samples were again tested for S1 ). The post-infusion samples again showed significantly increased levels of [Asc -] ss when spiked with MnT4MPyP, from 400 6 85 nM to 680 6 60 nM, indicating that a greater than 50% increase in ascorbate oxidation during radiation treatment is potentially achievable with the addition of MnT4MPyP (Fig. 5) .
DISCUSSION
Radiation treatment is the standard-of-care therapy for PDAC in a variety of clinical indications ranging from curative to palliative intent. Thus, agents that increase the tumoricidal effect of radiation, which may conceivably prolong survival, are of great interest. Previously published studies from our laboratory have suggested that both manganoporphyrins and radiation, when combined with PAscH -, will increase tumor cytotoxicity (4, 21) . Furthermore, our previously reported work has demonstrated that manganese porphyrins, such as MnT4MPyP, are capable of enhancing P-AscH -oxidation, leading to overall toxicity. Others have also reported on the radioprotective effects generated from MnPs on normal tissue (23) . It is therefore reasonable to investigate a treatment regimen that combines MnT4MPyP and P-AscH -in the presence of radiation. To our knowledge, this is the first published in-depth investigation into the tumoricidal effects of a combined treatment regimen consisting of MnT4MPyP and P-AscH -as a radiosensitizer in PDAC.
Our in vitro and in vivo studies presented here have demonstrated the potential of this potent treatment combination of MnT4MPyP, P-AscH -and radiation. We have shown that tumor cells treated with MnT4MPyP combined with P-AscH -are exposed to an oxidative flux that is far greater than MnT4MPyP or P-AscH -alone. We also demonstrate the marked increase in toxicity when tumor cells treated with combined MnT4MPyP and P-AscH -undergo radiation treatment. As our dose modification modeling illustrates, there is an increase in radiation toxicity with this multimodal approach. The capacity for each additional radiation dose to induce tumor cell toxicity is increased in cells treated with MnT4MPyP and P-AscH -compared to untreated cells. However, when normal pancreatic ductal epithelial cells are treated with MnT4MPyP and P-AscH -, then subsequently irradiated, there is no increase in radiation potency, indicating a selective toxicity for neoplastic cells.
These experiments demonstrated the increased sensitivity of PDAC to radiation in the presence of this combination treatment without any increase in radiosensitivity to normal pancreatic ductal epithelial cells. The 3D cell culture model highlights the potency of this treatment regimen. When tumor cells embedded in stromal cells and a biomatrix are treated in isolation with either MnT4MPyP, P-AscH -or radiation, there was no observed effect on cell growth. Previously published experiments from our laboratory in the Mia PaCa-2 cell line show a less than 10% cell survival in clonogenic survival experiments at similar treatment doses, but the simulated microtumor milieu in 3D cell cultures insulate the tumor cells from treatments added to the media. When 3D cultures were treated with a combination of MnT4MPyP and P-AscH -, a decrease was appreciated and escalating doses of radiation further increased the toxicity. ] ss levels were measured (400 6 85, nM, n ¼ 6); MnT4MPyP (1 lM) was added to these plasma samples and again, the [Asc - ] ss significantly increased (680 6 6 nM, n ¼ 6; *P , 0.05, means 6 SEM).
Previously published studies have shown that the enhanced flux of oxidants produced by P-AscH -leads to an increase in tumor toxicity (6) Clinical trials for the use of P-AscH -in PDAC are ongoing. A phase I clinical trial utilizing P-AscH -with standard-of-care chemotherapy for patients with nodepositive or metastatic PDAC demonstrated an exceptionally low toxicity profile with suggestion of treatment efficacy (7) . Others have reproduced these results in a similar phase I/IIa study (8) . In the future, manganese porphyrins may be considered as an investigational treatment regimen to add additional tumor toxicity and normal tissue protection. It is conceivable that agents such as these could enable an increase in the allowable radiation doses, making it possible for a greater proportion of patients with locally advanced disease to become resectable with a chance for disease control or even cure. Fig. S1 . Plasma samples from patients enrolled in the Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer Phase I clinical trial (NCT01852890) were collected at various time points within the study period. Pretreatment samples were collected prior to beginning the six-week trial, incorporating daily P-AscH -infusions concurrently with gemcitabine and radiation therapy (n ¼ 3). Pre-infusion samples were collected immediately before P-AscH -infusions during weeks 3 and 6 of the treatment cycle (n ¼ 4). Post-infusion samples were collected immediately after P-AscH -infusions during weeks 3 and 6 of the treatment cycle (n ¼ 6). Control plasma samples were collected from patients in the third or sixth weeks of the standard chemoradiation cycle who did not receive P-AscH 
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